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introduction: Based on many preclinical and small clinical trials, stem cells can help 
stroke patient with the possibility of replacing the cells and supporting the remaining 
cells. The aim of this study was to evaluate the safety and feasibility of bone marrow 
mononuclear (BMMN) stem cell transplantation in subacute ischemic stroke patients.
Materials and methods: Thirty-nine (n = 39) patients with subacute ischemic cere-
bral infarct due to large artery occlusion in the middle cerebral artery (MCA) territory 
were recruited. They were distributed into two groups: first group (n = 21) served as 
an experimental group, which received intra-arterial (IA) mononuclear stem cells (bone 
marrow-derived mononuclear cell), while the other group (n = 18) served as a control 
group. All the patients were evaluated clinically by National Institutes of Health Stroke 
Scale, modified Rankin Scale, Barthel Index, modified and standardized Arabic version 
of the Comprehensive Aphasia Test, and radiological for 12 months.
results: The stem cell-treated group showed better improvement, but it was not sig-
nificant when compared with the non-treated group. The volume of infarction changes 
at the end of the study was non-significant between both the groups. There was no, or 
minimal, adverse reactions in stem cell-treated group.
conclusion: The study results suggest that autologous BMMN stem cell IA transplan-
tation in subacute MCA ischemic stroke patients is safe with very minimal hazards, but 
no significant improvement of motor, language disturbance, or infarction volume was 
detected in stem cell-treated group compared with the non-treated group.
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inTrODUcTiOn
Stroke represents the third cause of death, followed by cancer and myocardial infarction. Its morbid-
ity and mortality keep increasing during the past few years, especially in developing countries (1).
The prevalence of non-fatal stroke in Egypt is 5.6 per 1,000 populations (2), and the disability-
adjusted life years (the sum of life years lost as a result of premature death and years lived with 
disability adjusted for severity lost per 1,000 population) was 8 in 2003 (3).
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Despite the availability of active therapies as thrombolytic 
therapy and percutaneous intravascular interventions, many 
patients suffering from stroke often remain disabled (4). These 
post-stroke disabilities have attracted the attention of researchers 
to explore more effective and safer treatments. Stem cells offer the 
promise of a novel neurorestorative strategy for acute brain injury. 
Recent preclinical studies in rodent stroke model using stem cell 
therapy have demonstrated significant behavioral recovery and, 
in some cases, reductions in lesion volume (5).
Although there are many types of stem cells, bone marrow-
derived mononuclear cells (BM-MNCs) represent one of the 
most convenient types for clinical use, as they can be isolated 
rapidly from autologous bone marrow without culture (6).
There are many potential mechanisms of cellular therapy by 
which transplanted stem cells are able to locate to the infarcted 
brain area and differentiate into neuronal and glial phenotypes; 
there is evidence that cell replacement could contribute to the 
reestablishment of neuronal circuits by increasing the sprouting 
of nerve fibers (7).
In the experimental model of stroke, intravenous, intra- 
striatal, and intra-arterial (IA) infusion of mononuclear stem cells 
have improved neurological outcome through reduced apoptosis 
and decreased peri-infarct inflammation and angiogenesis (8).
The aim of this study is to assess the safety and feasibility of 
autologous bone marrow mononuclear (BMMN) stem cells in 
managing patients suffering from large artery ischemic stroke in 
the territories of middle cerebral artery (MCA) in the subacute 
stage. This study was approved by the ethical committee of Faculty 
of Medicine, Tanta University, Egypt.
PaTienTs anD MeThODs
Thirty-nine patients with ischemic cerebral infarction due to 
large artery occlusion in the MCA territories in the subacute stage 
(1 week and up to 3 months) were enrolled in this study. None of 
them had the chance to receive thrombolytic therapy as an early 
treatment of ischemic stroke, and they were encoded by numbers 
to maintain their privacy.
Patients were distributed (according to their choice) into one 
of the two groups: the first group consisted of stem cell-treated 
patients (SCTPs), which included 21 patients who received 
autologous BMMN stem cell by IA (internal carotid) infusion 
ipsilateral to the infarction side at one session and continued 
on medical treatments according to the stroke guidelines of 
American Heart Association/American Stroke Association (9). 
The second group consisted of non-stem cell-treated patients 
(NSCTPs), which included 18 patients who served as control 
received medical treatments according to the stroke guidelines 
(9). An informed consent was obtained from all the participants 
or their first-degree relatives.
Patients enrolled in this study had ischemic stroke lasting 
for more than 1 week and less than 3 months; the neuro-images 
showed cerebral infarct in the MCA territory. Their National 
Institutes of Health Stroke Scale (NIHSS) between 4 and 20 and 
spontaneous re-canalization of the MCA were documented using 
transcranial Doppler.
Patients with cardio-embolic stroke, ASPECT score less than 
5/10, severe carotid stenosis (>70%, by Doppler), primary hema-
tological disease, neurodegenerative disorder, previous stroke 
with modified Rankin Scale (mRS) >2, auto-immune disorders, 
liver failure, chronic renal failure, or lacunar stroke were excluded 
from the study.
All the participants were evaluated by detailed medical history, 
physical examination, and neurological assessment that included 
the NIHSS, mRS, and Barthel index (BI). Patients with language 
disturbance were assessed by modified and standardized Arabic 
version of the Comprehensive Aphasia Test (10).
Neuro-imaging including brain CT or MRI to confirm ischemic 
stroke lesion site and excluding other intracranial pathology were 
obtained. Carotid system was assessed by linear array transducer 
of multi-frequency (3–12 MHz), real-time, sagittal, coronal, and 
axial views, while intracranial vessels were assessed by phased 
array transducer of multi-frequency (1–3  MHz), trans-axial, 
mesencephalic view through temporal window.
Laboratory tests including complete blood count and bio-
chemical tests for urea, creatinine, electrolytes, fasting and post-
prandial blood sugar, coagulation profile, and serum cholesterol 
and triglyceride were performed.
Stem cell-treated patients were submitted to bone marrow 
aspiration, which is a standard practice at clinical pathology 
department in molecular diagnosis of hematological disease, 
Tanta University Hospital, which has been in use for many years. 
Three days before the procedure, patients received a daily SC 
injection of granulocyte colony stimulating factor (Pegfilgrastim) 
(Geneleukim®) (G-CSF at 300 μg/vials).
After aspiration of 50–100 ml of the BM, they were diluted at 
a ratio of 2:1 with clinical buffer; then, bone marrow filter was 
wetted with clinical buffer before use, and then, the diluted BM 
passed through it using sterile Pasteur tubes. Then, 35 ml of the 
diluted cell suspension was carefully layered over 15 ml of ficoll 
paque in a 50-ml conical tube and centrifuged at 2,000  rpm 
for 20  min at 20°C in a swinging out bucket rotor without 
brake. The interphase cells (mononuclear cells including SC 
and thrombocytes) were carefully transferred to a new 50-ml 
conical tube.
Cell pellet was washed by adding up to 40 ml of clinical buffer, 
mixed gently, and centrifuged at 1,200 rpm for 15 min at 20°C. 
Then, the supernatant was carefully and completely removed (this 
step was done twice) and finally cell pellet was suspended in an 
appropriate amount of clinical buffer.
The IA infusion was carried out a few minutes after separation 
of bone marrow SC using a Toshiba digital subtraction angiog-
raphy (DSA). Patients were brought to the angiography suite and 
placed in the supine position, and an 18- or 20-gauge IV line is 
started. Ascending through the RT femoral artery to the aorta 
by diagnostic catheter and guiding hydrophilic J-shaped wire 
to reach the aortic arch, and from there, we select either right 
or left common carotid artery, then the internal carotid artery, 
and begin infusion of stem cells. After infusion of about 1 × 106 
cells suspended in 100-ml saline, the catheters and sheaths were 
removed, and hemostasis was achieved by either manual com-
pression or with the use of a closure device.
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FigUre 1 | Baseline medical condition, comorbidities, and risk factors of stroke between both groups.
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All SCTPs were evaluated every hour for the first 24 h for vital 
signs, any neurological deterioration, and anaphylactic reaction, 
and then every day for the following week.
All patients in both groups were followed up monthly for 
neurological assessment using NIHSS, mRS, and BI, and patients 
with language disturbances were assessed by modified and stand-
ardized Arabic version of the Comprehensive Aphasia Test.
Neuro-imaging including brain CT to follow volume changes 
of infract area was carried out every 4 months for 1 year. For the 
assessment of volume of infarction, we used Toshiba Aquilion 
16 CT Scanner®. The images were displayed and analyzed via 
DICOM 3.0 standards software. Using the manual tracing tech-
nique (this was carried out by trained radiologist, blind to cases), 
the perimeter of the area of abnormal low attenuation was traced 
on each CT slice showing the infarct, and the software automati-
cally calculates the surface area being traced. The sum of all areas 
traced in all CT slices multiplied by the thickness of the slice is 
the infarction volume.
statistical analysis
Statistical presentation and analysis of the present study was con-
ducted, using the mean, SD, and chi-square test by SPSS V.16. In 
all of the statistical analysis, p < 0.05 was regarded as statistically 
significant.
resUlTs
Twenty-one patients were included in the SCTPs group (12 males 
and 9 females with their age ranged between 46 and 66 years). 
While NSCTPs consisted of 18 patients (10 males and 8 females 
with their age ranged between 48 and 65 years) who served as 
control and received regular treatments according to the stroke 
guidelines.
The earliest day of stem cells infusion was 12 days post-stroke 
onset, and the latest day was 32  days post-stroke onset with a 
mean of 22 days post-stroke onset.
There were no significant differences between the groups with 
respect to comorbidities and risk factors of stroke (Figure  1). 
There were 24 patients with hypertension (61.9% of SCTP group 
and 61.1% of NSCTP group), 21 patients with diabetes mellitus 
(52.4% of SCTP group and 55.6% of NSCTP group), 18 patients 
were smokers (52.4% of SCTP group and 38.9% of NSCTP group), 
8 patients had coronary artery disease (19% of SCTP group and 
22.2% of NSCTP group), 5 patients had previous cerebrovascular 
strokes (9.5% of SCTP group and 18.7% of NSCTP group), and 
13 patients had dyslipidemia (38.1% of SCTP group and 27.1% 
of NSCTP group).
clinical Outcomes
At the beginning of this study, the NIHSS was not significant in 
both groups (p = 0.364). At the fourth month of the follow-up, we 
found significant improvement in NIHSS within each group, but 
this improvement was not statistically significant on comparison 
(p = 0.376; Figure 2). The initial mRS was not significant in both 
groups (p =  0.452), while at the end of the study, both groups 
showed significant improvement in mRS, without statistical 
significance between them (p = 0.290; Figure 3).
Also, the baseline BI was not different in both groups (p = 0.84), 
while at 12 months of follow-up, we found statistically significant 
improvement in BI within each group, but this improvement was 
not statistically significant on comparison (p = 0.745) (Figure 4). 
The language deficit was assessed by modified and standardized 
Arabic version of the Comprehensive Aphasia Test, which was 
not significant in both groups at the beginning of the study 
(p = 0.513). At the end of the study, we found significant improve-
ment within each group, without significant difference between 
both groups (p = 0.691) (Figure 5).
radiological Outcomes
At the beginning of this study, the difference of volume of infarc-
tion was not significant in both groups (p = 0.606). At the end 
of the study, the changes in the volume of infarction between 
both groups were minimal (p = 0.602); even within each group 
separately, there was no significant changes from baseline 
(Figure 6).
safety and Trial conduct
In our study, two patients developed ecchymosis at the site of 
BM aspiration (9.5%) and they did not need any intervention. 
Mild pain was present in all patients after several hours of BM 
aspiration (100%), which was relieved totally with a single dose 
of NSAIDs.
One of our patients died 5  months post-procedure due to 
severe chest infection followed by respiratory failure and death. 
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FigUre 4 | Follow-up of both groups by Barthel index.
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None of our patients developed either systemic or intracranial 
infection, embolic complication, seizure, or tumor formation 
during the study period. One patient in the SCTPs group devel-
oped mild renal impairment 3  months post-procedure, which 
improved on conservative treatment. One patient in NSCTPs 
group developed recurrent cerebrovascular stroke, and another 
patient developed mild renal impairment, which improved on 
conservative treatment.
±17.49
±19.15
±18.88 ±18.9
±14.06
±16.41
±19.25 ±19,71
0
5
10
15
20
25
30
35
Baseline 4th month 8th month 12th month
SCTPs NSCTPs
FigUre 5 | Follow-up of both groups by modified and standardized arabic version of the comprehensive aphasia Test.
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DiscUssiOn
A major advantage of cell therapy is that it will open the thera-
peutic time window of ischemic stroke such that a larger patient 
population will get benefit. This time window is 3 to 6h longer 
than that required for thrombolytic therapy (11). Preclinical stud-
ies demonstrated that the use of bone marrow stem cells had ben-
eficial outcome in behavioral improvement in a rat stroke model. 
However, translating this early success into clinical applications 
was difficult due to both the limitation in source tissue and the 
ethical concerns (12–14).
When we started on designing this study, we put in our consid-
eration that stroke is a heterogeneous disease that typically affects 
elderly people with significant comorbidities such as hyperten-
sion, atherosclerosis, cardiac disorders, and diabetes mellitus. In 
addition, female hormonal profile may play role as risk factors 
for stroke and affect response to treatment. So, to avoid all these 
variances affect our study results, we recruited 39 patients with 
ischemic cerebral infarct due to large artery occlusion in the 
MCA territories in subacute stage; none of them had the chance 
to receive thrombolytic therapy as early treatment of ischemic 
stroke, and this was intended to avoid good prognostic effect of 
tPA on clinical outcome.
In this study, only patients with partial MCA ischemic stroke 
were recruited and patients with ASPECT score less than 5 were 
excluded due to the expected bad prognosis, and theoretically, 
scaffolding and repeated doses of stem cell were required to cover 
this huge area of infarction.
Our results proofed safety of BMMN transplantation and 
agree with Prasad et al. (15) who found that all procedures were 
totally safe, as no serious adverse events were observed during 
their study. Also, Battistella et al. (16) assessed the safety and fea-
sibility of IA transplantation of BMMN stem cells in six patients 
suffering from infarction in the MCA territories within 90 days 
of symptom onset; their results showed no stroke recurrence or 
cell-related adverse events during the procedure or during the 
follow-up period of 180 days.
The assessment of clinical outcome showed a functional 
improvement in both groups; however, the SCTPs showed better 
scores in NIHSS, mRS, and BI; this improvement was not statisti-
cally significant when compared to the NSCTPs. This finding was 
the same when we assessed language improvement.
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The favorable outcomes were confirmed by the previous work 
of Prasad et al. (8), as they reported non-significant improvement 
in BI in their patient when compared to the control group. Also, 
Moniche et al. (17) reported non-significant changes of BI after 
IA BMMN stem cells infusion.
On the other hand, Bhasin et  al. (18) reported statistically 
significant improvement in modified BI after 24 weeks between 
stem cell group and control group; however, they did not find 
significant changes in functional MR imaging in both groups. 
After we reviewed their patients and methods, we found that they 
infused both mononuclear and expanded mesenchymal stem cells 
intravenous in patients with ischemic and hemorrhagic stroke, 
which could explain the difference between our results and theirs.
Also, Suárez-Monteagudo et  al. (19) reported a significant 
improvement in equilibrium, locomotion, and increased func-
tional capacity in five patients who received intracerebral stem 
cell. Tthis conclusion could be explained by the small sample size, 
lack of control group, and recruiting patients with hemorrhagic 
stroke.
Lee et al. (20) reported improvement in mRS score after long-
term follow-up (5 years) in patients who received IV mesenchymal 
stem cells when compared to the control group. When we revised 
their patients’ characteristic, we found that 12 patients received 
thrombolytic therapy during acute stroke, so we can claim that 
the improvement may be related to thrombolytic therapy and not 
related to stem cells effect.
Unfortunately, there were no clinical trials to assess language as 
an outcome of stem cell therapy in stroke patient. This is because 
most of the researchers were focusing on assessing safety as the 
primary outcome and motor deficit as the secondary outcome.
There is a case report by Bringas et al. (21), which reported a 
case of a 55-year-old Caucasian woman who received intracer-
ebral autologous bone marrow stem cell 3 years after a subcortical 
stroke; she exhibited positive cognitive changes 6  months and 
1 year after the surgery without rehabilitation. One year later, she 
showed improvement in mental flexibility, receptive language, 
phonological fluency, verbal memory, and auditory verbal 
memory.
Regarding the changes of infarction volume in both groups, 
our results showed no significant changes within each group even 
when comparing both groups. These results agreed with that of 
the previous work by Bhasin et al. (18); however, they reported 
that the stem cell group showed more functional improvement, 
but they did not find significant difference in functional brain 
MRI between experimental and control groups at 8 weeks and 
6  months post-treatment. Also, Friedrich et  al. (22) reported 
non-significant difference in infarct volumes or infarct densities 
between groups with and without clinical improvement.
Mendonça et al. (23) reported an improvement in the ischemic 
area assessed by MRI diffusion and in hypo-perfusion by SPECT 
7 days post-mononuclear stem cell IA transplantation at 3 days 
post-stoke onset. But this was only a case report and the patient 
received cell therapy early on third day of admission, and this 
improvement in image may be a result of improvement, which 
was due to resolved brain edema and revascularization as stem 
cells need more time to differentiate into neuron or vascular 
endothelial cells.
In the present study, we carried out BMMN stem cell trans-
plant in the early subacute stage. The procedure day after stroke 
onset is 22 ± 5.56. We selected this time window upon revision 
of preclinical trials (24, 25). Also, stroke patients are liable for 
deterioration in early days either by the effect of cerebral edema 
or hemorrhagic transformation. Finally, some patients with 
ischemic stroke have spontaneous recovery; so, we selected the 
subacute stage to be sure that the patients have stable deficit due 
to ischemic stroke.
On the contrary, in most of the preclinical studies, stem cells 
were given <24 h after ischemia (26). This is partly because of 
the opening of the blood–brain barrier after cerebral ischemia, 
which allows cells to enter the brain parenchyma. Also, the 
expression of various chemotactic signals peaks at this time point 
and guides the cells toward ischemic areas. However, while early 
cell transplantation may provide neuroprotection, the hostile 
environment endangers the long-term survival of transplanted 
cells. Transplantation at later time points may target the process 
of neurodegeneration and enhance the brain’s own repair mecha-
nisms (27).
In this study, we selected the IA route as it involves endovas-
cular infusion of stem cells directly in the artery perfusing the 
infarcted tissue. This route has the advantage of bypassing the 
peripheral filtering organs, thereby increasing the dose of cell 
delivered to the target tissue with uniform distribution.
One study comparing IV versus IA autologous BM-MNC 
infusion reported significant reduction in infarct volume, higher 
cell engraftment, and improved motor function in favor of the 
IA route. The authors attributed this “significant neuroprotective 
effect” in the IA group to the higher number of implanted cells in 
the brain during early reperfusion (28).
Finally, it has been hypothesized that infused stem cells were 
not only preferentially home in the infarcted brain but also secrete 
neurotrophic growth factors and act as “scaffolds” making the 
host environment appropriate for behavioral recovery and help 
endogenous neurogenesis after stroke. In addition to local effects 
on the damaged tissue, transplanted cells may help in recruit-
ing progenitor cells from other tissues, as they could mobilize 
endogenous endothelial progenitors into circulation to enhance 
angiogenesis (29).
cOnclUsiOn
Our results suggest that autologous BM-MN stem cell IA trans-
plantation in subacute MCA ischemic stroke is safe with very 
minimal hazards, but no significant improvement of motor, 
language disturbance, or volume of infarction was detected in 
treated group when compared with the control group.
study limitations
The limited sample size of patient and the absence of implanted 
cell tracking in vivo were the main limitations of this study.
recommendation
Large trials should be planned with stroke patients for getting 
appropriate decision about application of stem cells in clinical 
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approach. Also, testing different types of stem cells, early injec-
tion of stem cells in the acute stage of stroke, and repeated booster 
doses of stem cell transplantation may be more beneficial than 
single injection. Finally, monitoring of survival, migration, and 
function of these cells by non-invasive imaging may reveal their 
fate in the host brain.
eThics sTaTeMenT
Study approved by the Quality Assurance Unit, Research Ethics 
Committee, Faculty of Medicine Tanta University, approval 
number 593/05/11. The consent for participation in this study 
was signed by first degree relative in case of patients with lan-
guage disturbance.
aUThOr cOnTriBUTiOns
EE was responsible for stem cell separation and preparation. OR 
was responsible for recruiting patients’ clinical and radiological 
follow-up and shared intra-arterial stem cell infusion. MY was 
responsible for intra-arterial stem cell infusion. AG was respon-
sible for recruiting patients’ clinical and radiological follow-up.
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